Nirvana Life Sciences Inc.
NIRV
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -58.79% | -70.10% | -59.77% | -24.19% | -36.70% |
| Depreciation & Amortization | -- | -- | -73.37% | -47.06% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -64.27% | -76.85% | -56.14% | -25.02% | -39.54% |
| Operating Income | 64.27% | 76.85% | 56.14% | 25.02% | 39.54% |
| Income Before Tax | 63.88% | 84.87% | 50.79% | 102.11% | 39.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.88% | 84.87% | 50.79% | 102.11% | 39.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -33.33% | -75.00% | -86.67% | -76.92% | 200.00% |
| Net Income | 63.87% | 84.89% | 50.70% | 102.30% | 39.95% |
| EBIT | 64.27% | 76.85% | 56.14% | 25.02% | 39.54% |
| EBITDA | 61.46% | 76.36% | 55.16% | 18.21% | 43.33% |
| EPS Basic | 65.38% | 87.50% | 65.36% | 101.96% | 57.38% |
| Normalized Basic EPS | 62.50% | 88.37% | 70.49% | 103.13% | 57.89% |
| EPS Diluted | 65.38% | 87.50% | 65.36% | 101.96% | 57.38% |
| Normalized Diluted EPS | 62.50% | 88.37% | 70.49% | 103.13% | 57.89% |
| Average Basic Shares Outstanding | 0.00% | 14.75% | 42.04% | 41.72% | 41.72% |
| Average Diluted Shares Outstanding | 0.00% | 14.75% | 42.04% | 41.72% | 41.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
